Search results
Results from the WOW.Com Content Network
Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis. It is a humanized anti- CD20 monoclonal antibody . [ 8 ] It targets CD20 marker on B lymphocytes and is an immunosuppressive drug . [ 10 ]
In March 2017, ocrelizumab was approved in the United States for the treatment of primary progressive multiple sclerosis in adults. [22] [42] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. [42]
In Canada, nabiximols has been approved by Health Canada for the treatment of MS spasticity. It has also received a licence with conditions (NOC/c) for two additional uses: as adjunctive treatment for the symptomatic relief of neuropathic pain in multiple sclerosis, [12] and also for pain due to cancer. [13] [14]
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. [13] Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions.
In the United states, natalizumab is indicated for the treatment of multiple sclerosis and Crohn's disease. [1] [9] It is indicated to treat clinically isolated syndrome – a single, first occurrence of multiple sclerosis symptoms; relapsing-remitting disease – a type of multiple sclerosis that occurs when people have episodes of new neurological symptoms followed by periods of stability ...
Multiple studies have shown that low-dose naltrexone has promise as a treatment for chronic pain, some autoimmune disorders and cancers. [8] [9] [10] As of 2014, no peer-reviewed studies supporting low-dose naltrexone for multiple sclerosis (MS) have been published. [11] [12] Clinical trials for treatment of fibromyalgia were initiated in 2021 ...
Glatiramer acetate, sold under the brand name Copaxone among others, is an immunomodulator medication used to treat multiple sclerosis. [1] [2] Glatiramer acetate is approved in the United States to reduce the frequency of relapses, but not for reducing the progression of disability.
Main symptoms of multiple sclerosis Symptoms and findings in multiple sclerosis. Multiple sclerosis can cause a variety of symptoms varying significantly in severity and progression among individuals: changes in sensation (hypoesthesia), muscle weakness, abnormal muscle spasms, or difficulty moving; difficulties with coordination and balance; problems in speech or swallowing (), visual ...